Clinical Trial

Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This exploratory project will assess the acceptability and feasibility of monthly extended-release subcutaneous buprenorphine (BRIXADI; XR-B) to treat opioid use disorder (OUD) among persons in the community receiving care on a mobile pharmacy clinic (MPC). Participants who are interested in initiating monthly or weekly injections of subcutaneous XR-B (BRIXADI) as a treatment for their OUD will be enrolled in a 6-month study assessing the acceptability and feasibility of receiving XR-B on an MPC.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-08; most recent amendment 2026-04-01.
Trial Details
NCT Number NCT07176351
Lead Sponsor Yale University
Collaborators: Braeburn Pharmaceuticals
Conditions Opioid Use Disorder
Enrollment 60 participants
Start Date 2026-08
Primary Completion 2027-02 (estimated)
Study Completion 2027-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-31